

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended

CT Healthcare Trust plc (the "Company")

Quarterly Tender Offer Tender Price

LEI: 213800HQ3J3H9YF2UI82

2 September 2026

Further to the quarterly tender offer launched by the Company on 6 August 2026 (the "**Tender Offer**") for up to 15 per cent. of the Company's issued Shares (excluding any Shares held in treasury), the Company announces that the Tender Price at which all Shares accepted in the Tender Offer will be acquired is 137.2829 pence per Share.

The Tender Price has been determined by reference to the Company's prevailing NAV per Share at close of business on the Calculation Date of 1 September 2026, less the Tender Offer Expenses per Share.

It is intended that Shares successfully tendered under the Tender Offer will be purchased by J.P. Morgan Cazenove on 16 September 2026 and settlement of the Tender Offer will occur as soon as practicable, and by no later than 10 Business Days, thereafter. All Shares acquired by the Company will be held in treasury.

Terms used and not otherwise defined in this announcement shall have the meanings given to them in the Company's circular to Shareholders dated 6 August 2026 setting out the terms and conditions of the Tender Offer.

For further information, please contact:

CT Healthcare Trust plc

Sarah MacAulay, Chairman

Columbia Threadneedle Investments **+44 (0) 207 464 5000**

Marrack Tonkin, Head of
Investment Trusts

JP Morgan Cazenove **+44 (0) 20 3493 8000**

William Simmonds / Rupert
Budge

Company Secretary

Columbia Threadneedle Investments **+44 (0) 131 573 8372**

Scott McEllen

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TENLLLFQBQLFBBE